LEO Pharma recently announced that Enstilar Foam for plaque psoriasis has been approved by the U.S. Food and Drug Administration.
Psoriasis is a chronic, inflammatory skin disease that often comes with of physical and psychological symptoms. Psoriasis affects approximately two to four percent of people in western countries, and 80 percent of psoriasis patients are affected by psoriasis vulgaris.
"We are very pleased by the U.S. approval of Enstilar and believe it will provide patients with the type of treatment option that they are looking for," Gitte Aabo, president and CEO of LEO Pharma, said. "At LEO Pharma, we are committed to providing patients with innovative, new solutions and we believe the foam formulation of Enstilar can help patients living with psoriasis."
Enstilar Foam is a once-a-day, alcohol-free topical treatment intended for the treatment of psoriasis vulgaris in patients 18 years of age or older.
The FDA approved Enstilar due to a positive study that assessed the efficacy and safety of Enstilar during a four-week period. Enstilar functions by normalizing the affected skin cells through the use of a vitamin D analogue and potent corticosteroid.
LEO Pharma, headquartered in Denmark, specializes in dermatology and critical care.